Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Treatment of astrocytes-tumor cells inhibitors of endothelin receptors

a technology of endothelin receptor and astrocytes, which is applied in the field of treatment of astrocytestumor cells inhibitors of endothelin receptor, can solve the problems of poor limited medical options for brain metastasis, temozolomide appears to have some limited effect on response rate, and the difficulty of brain metastasis, etc., to achieve the effect of maintaining homeostasis

Inactive Publication Date: 2015-12-10
BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a combination of an endothelin receptor antagonist and a cytotoxic chemotherapy agent for the prevention or treatment of brain metastases. The endothelin receptor antagonist can be used with various chemotherapy agents such as alkylating agents, platinum drugs, antimetabolite drugs, anti-tumor antibiotics, and mitotic inhibitors. The combination can help protect neurons from damage and reduce the risk of brain metastasis.

Problems solved by technology

Brain metastasis is one of the most difficult challenges facing oncology.
Results are preliminary but temozolomide appears to have some limited effect on the response rate compared to radiation alone and appears to have some clinical activity in combination with radiation in phase II trials.
Despite intense efforts, the limited medical options available for brain metastasis have remained poor and too often more palliative than therapeutically effective.
This state of affairs has been long recognized but, to date, significant advances have not materialized.
Thus, one of skill in the art realizes that a treatment may improve the patient's condition but may not be a complete cure of the disease.
(2000), Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of astrocytes-tumor cells inhibitors of endothelin receptors
  • Treatment of astrocytes-tumor cells inhibitors of endothelin receptors
  • Treatment of astrocytes-tumor cells inhibitors of endothelin receptors

Examples

Experimental program
Comparison scheme
Effect test

embodiment 1

2) According to one main variant of embodiment 1), the endothelin receptor antagonist will be for use in combination with a cytotoxic chemotherapy agent.

embodiment 2

3) According to one sub-embodiment of embodiment 2), the cytotoxic chemotherapy agent will comprise (and in particular be) an alkylating agent.

embodiment 3

4) In particular, the alkylating agent of embodiment 3) will be selected from the group consisting of mechlorethamine, chlorambucil, cyclophosphamide, iphosfamide, streptozocin, carmustine, lomustine, melphalan, busulfan, dacarbazine, temozolomide, thiotepa and altretamine.

5) According to another sub-embodiment of embodiment 2), the cytotoxic chemotherapy agent will comprise (and in particular be) a platinum drug.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Cytotoxicityaaaaaaaaaa
Login to View More

Abstract

The disclosure relates to an endothelin receptor antagonist for use in the prevention or treatment of brain metastases in combination with a cytotoxic chemotherapy agent, radiotherapy or both. The endothelin receptor antagonist may for example be bosentan, macitentan or a mixture of bosentan and macitentan.

Description

BACKGROUND[0001]Brain metastasis is one of the most difficult challenges facing oncology. Metastatic tumors are resistant to most chemotherapy agents. The treatments for brain metastasis are primarily whole brain and focused radiotherapy, with surgical resection of tumors in a minority of cases. Most chemotherapy regimens involve 2-3 agents such as cisplatin, cyclophosphamide, etoposide, teniposide, mitomycin, irinotecan, vinorelbine, etoposide, ifosfamide, temozolomide and fluorouracil (5-FU). These are administered in combination with radiotherapy. The effect of these chemotherapies on prolonging survival is generally less than a year. A fairly new chemotherapy for brain tumors is temozolomide used with whole-brain irradiation. Results are preliminary but temozolomide appears to have some limited effect on the response rate compared to radiation alone and appears to have some clinical activity in combination with radiation in phase II trials.[0002]Despite intense efforts, the limi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/513A61N5/10A61K31/337
CPCA61K31/513A61N5/1084A61K31/337A01K67/027A01K2227/105A01K2267/0331A61K31/506C12N5/0622C12N5/0693C12N2502/08C12N2502/30G01N33/5008A61K45/06A61K31/495A61P35/00A61P35/04A61P43/00A61K2300/00A61K31/4188
Inventor FIDLER, ISAIAHKIM, SUN-JIN
Owner BOARD OF RGT THE UNIV OF TEXAS SYST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com